Table 1 Baseline characteristics of matched persons in the target trial emulation evaluating the comparative effectiveness of a third dose of BNT162b2 and mRNA-1273 vaccines during a period spanning Delta- and Omicron-variant predominance

From: Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans

Characteristic

BNT162b2 recipients (N = 65,196)

mRNA-1273 recipients (N = 65,196)

Median age (IQR) (yr)

70.0 (62.0, 74.0)

70.0 (62.0, 74.0)

Age group, no. (%)

18–39 yr

1,005 (1.5)

1,028 (1.6)

40–49 yr

2,247 (3.4)

2,217 (3.4)

50–59 yr

8,687 (13.3)

8,614 (13.2)

60–69 yr

20,029 (30.7)

20,092 (30.8)

70–79 yr

27,623 (42.4)

27,635 (42.4)

≥80 yr

5,605 (8.6)

5,610 (8.6)

Sex, no. (%)

Male

62,485 (95.8)

62,485 (95.8)

Female

2,711 (4.2)

2,711 (4.2)

Race, no. (%)

Black

15,365 (23.6)

15,365 (23.6)

Other

705 (1.1)

705 (1.1)

Unknown

1,013 (1.6)

1,013 (1.6)

White

48,113 (73.8)

48,113 (73.8)

Ethnicity, no. (%)

Hispanic

4,224 (6.5)

5,878 (9.0)

Not Hispanic

59,446 (91.2)

57,848 (88.7)

Unknown

1,526 (2.3)

1,470 (2.3)

Urban residence, no. (%)

50,919 (78.1)

50,919 (78.1)

Smoking status, no. (%)

Current

21,926 (33.6)

23,013 (35.3)

Former

21,517 (33.0)

20,234 (31.0)

Never

21,753 (33.4)

21,949 (33.7)

Coexisting conditions, no. (%)

Chronic lung diseasea

10,715 (16.4)

11,913 (18.3)

Cardiovascular diseaseb

18,341 (28.1)

18,589 (28.5)

Hypertension

42,726 (65.5)

44,320 (68.0)

Diabetes

23,053 (35.4)

25,414 (39.0)

Chronic kidney disease

6,163 (9.5)

6,889 (10.6)

Chronic liver disease

2,540 (3.9)

2,241 (3.4)

Cancerc

8,877 (13.6)

8,936 (13.7)

Immunocompromised stated

3,707 (5.7)

4,213 (6.5)

Obesitye

30,091 (46.2)

30,714 (47.1)

Dementia

1,165 (1.8)

1,089 (1.7)

Substance use disorder

5,164 (7.9)

5,211 (8.0)

Months since completion of mRNA COVID-19 vaccine primary series, no. (%)

6–7

20,259 (31.1)

20,071 (30.8)

8

25,951 (39.8)

26,077 (40.0)

≥9

18,986 (29.1)

19,048 (29.2)

Vaccine type for mRNA COVID-19 vaccine primary series (compared with third dose type), no. (%)

Homologous

61,918 (95.0)

62,922 (96.5)

Heterologous

3,278 (5.0)

2,274 (3.5)

No. of SARS-CoV-2 tests performed in the past year, no. (%)

0

43,527 (66.8)

43,527 (66.8)

1

10,868 (16.7)

10,868 (16.7)

≥2

10,801 (16.6)

10,801 (16.6)

No. of primary care visits in the past 5 yr, no. (%)

1–9

4,541 (7.0)

3,545 (5.4)

10–19

21,014 (32.2)

18,301 (28.1)

20–29

18,356 (28.2)

18,833 (28.9)

≥30

21,285 (32.6)

24,517 (37.6)

No. of influenza vaccinations in the past 5 yr, no. (%)

0

9,240 (14.2)

7,667 (11.8)

1 or 2

11,974 (18.4)

10,120 (15.5)

3 or 4

23,236 (35.6)

22,222 (34.1)

≥5

20,746 (31.8)

25,187 (38.6)

  1. Persons included in this target trial emulation received a third dose of BNT162b2 or mRNA-1273 between 20 October 2021 and 8 February 2022.
  2. aChronic lung disease included asthma, bronchitis and chronic obstructive pulmonary disease.
  3. bCardiovascular disease included acute myocardial infarction, cardiomyopathy, cerebrovascular disease, coronary heart disease, heart failure and peripheral vascular disease.
  4. cNot included here are non-melanoma skin cancer, benign neoplasms, cancers in situ and neoplasms of uncertain behaviour.
  5. dImmunocompromised state included human immunodeficiency virus infection, organ or tissue transplant, bone marrow biopsy, or use of any of the following medications (prescribed ≥2 times over the past year): systemic glucocorticoids, anti-inflammatory or anti-rheumatic agents in combination with glucocorticoids and immunosuppressants.
  6. eObesity was defined as a body-mass index (the weight in kilograms divided by the square of the height in metres) of 30 or greater.
  7. IQR, interquartile range. Percentages may not total to 100% because of rounding.
Back to article page